This strategic acquisition combines BioCentric’s medical affairs and commercial expertise with JPA Health’s integrated services, predictive analytics and AI-driven solutions.
Getty ImagesRegeneron’s Phase I/II study is a first-in-human open-label trial testing the investigational antibody, in combination with the company’s PD-1 blocker Libtayo (cemiplimab-rwlc), as a treatment for patients with metastatic and locally advanced solid tumors who have exhausted standard treatment options.
Nimbus Therapeutics’ small molecule drug candidate NDI-101150 showed strong potential for clinical benefit in patients with advanced solid tumors, the Boston-based biotech announced.
Johnson & Johnson’s radiopharma candidate JNJ-6420 returned mixed results in an early-stage study, demonstrating strong biochemical and radiographic response but also resulting in four patient deaths.
Full data from the FLOW study show that Novo Nordisk’s top-selling GLP-1 receptor agonist semaglutide can significantly reduce the risk of death by 20% in diabetes patients with chronic kidney disease.
If approved, the test, called Shield, could become the second blood-based test for CRC screening in the United States after Epigenomics’ Epi proColon, which was approved in 2016.